These new drugs were designed to inhibit both the activating EGFR mutation in patients with NSCLC as well as the T790M resistance mutation, and showed a high positive response rate to T790M mutation-positive NSCLC of approximately 60% in phase I clinical trials [32]. Here, EGFR is linked to non-small cell lung carcinoma.